Taysha Gene Therapies assumed with an Overweight at Piper Sandler

Piper Sandler analyst Biren Amin assumed coverage of Taysha Gene Therapies (TSHA) with an Overweight rating and $9 price target The firm cites the potential of the company’s TSHA-102, an AAV9-based gene therapy for the treatment of Rett syndrome, for the Overweight rating. Taysha has thus far shared data from four Rett syndrome patients treated with low dose TSHA-102, with patients showing improvements in gross/fine motor skills, communication, and seizure burden, the analyst tells investors in a research note. The next update in Q2 should serve as a catalyst for the shares, contends Piper.